Citi analyst Hidemaru Yamaguchi upgraded Sumitomo Pharma to Neutral from Sell with a price target of 460 yen, up from 190 yen. The firm says Orgovyx is strong in the U.S. and appears to be outpacing guidance due partly to a decrease in patient copayments as a result of changes in the Medicare system.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNPUF: